Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-02-25
1993-04-13
Lee, Mary C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514367, 514372, 514373, 514380, 514389, A61K 31445, A61K 31425, A61K 31415
Patent
active
052023397
ABSTRACT:
The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives and pharmaceutical compositions containing at least one of hydantoin derivatives as hypoglycemic as well as hypolipidemic agents.
The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton. The compounds of the present invention have a strong inhibitory activity against aldose reductase. These compounds are extremely useful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.
The compounds of the present invention represent a satisfactory hypoglycemic as well as hypolipidemic activity. These compounds are extremely useful for the treatment and/or prevention of diabetes mellitus with or without hyperlipidemia. It is indicated that the compounds of the present invention are useful for the treatment and/or prevention of diabetic complications such as somatic or autonomic neuropathy, cataract, retinopathy, nephropathy or microangiopathy. It is also indicated that the compounds of the present invention are useful for the treatment and/or prevention of hyperlipidemia.
REFERENCES:
patent: 3384643 (1968-05-01), Sayigh et al.
patent: 3534022 (1970-10-01), Umemoto et al.
patent: 4575507 (1986-03-01), Lipinski
patent: 4656169 (1987-04-01), Schnur
patent: 4743611 (1988-05-01), Malamas et al.
Chemical Abstracts, vol. 95, No. 15, Oct. 12, 1981, Abstract No. 132725.
Chemical Abstracts, vol. 97, No. 1, Jul. 5, 1982, Abstract No. 6774e.
Chemical Abstracts, vol. 99, 1983, Abstract No. 116079f. Okuda, Hydantoins as aldose reductase inhibitors.
Chemical Abstracts, vol. 107, 1987, Abstract No. 59037y Okuda et al., Hydantoin . . . , inhibitors.
Chemical Abstracts, vol. 109, 1988, Abstract No. 129004c Okada et al., Preparation of . . . , reductase inhibitors.
Miwa et al., In Vivo Activities of Aldose Reductase Inhibitors, Biochemical Pharmacology, vol. 40, No. 2, pp. 303-307, 1990.
Miwa et al., Development of Potent Aldose Reductase Inhibitors, Biochemical Pharmacology, vol. 36, No. 17, pp. 2789-2794, 1987.
Miwa et al., Improvement of Nerve Conduction Velocity in Mutant Diabetic Mice, Chem. Pharm. Bull., vol. 37, No. 6, pp. 1581-1582, 1989.
Miwa et al., Hypoglycemic Activity of Aldose Reductase Inhibitor Chem. Pharm Bull., vol. 32, No. 5, pp. 2030-2032, 1984.
Okuda, Aldose Reductase Inhibitor, Patent Abstracts of Japan, vol. 7, No. 29 (C-186), 1983.
Okuda, Hydantoin Derivative and Aldose Reductase Inhibitor, Patent Abstracts of Japan, vol. 12, No. 56 (C-477), 1988.
Okuda, Hydantoin Derivative and Aldose Reductase Inhibitor, Patent Abstracts of Japan, vol. 11, No. 267 (C-443), 1987.
Kato Katsuaki
Kato Kazuo
Miwa Ichitomo
Mochida Ei
Murakami Kimihiro
Lee Mary C.
McKane Joseph K.
Mochida Pharmaceutical Co. Ltd.
LandOfFree
Hydantoin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydantoin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydantoin derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1155649